RGC
BIVV

Roberts, Glore & Co’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Roberts, Glore & Co’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7,279
Closed -$392K – 150
2017
Q4 		$392K Buy
7,279
+3,206
+79% +$175K 0.24% 95
2017
Q3 		$232K Buy
+4,073
New +$239K 0.15% 127

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Roberts, Glore & Co's BIVV Position: Q1 2018 in Review

Roberts, Glore & Co sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 7,279 shares — an estimated $392K sold.

Roberts, Glore & Co first reported a position in BIVV in Q3 2017 and held it in 2 quarters. The position peaked at $392K in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Roberts, Glore & Co reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Roberts, Glore & Co sold 7,279 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $392K.
  • Roberts, Glore & Co first reported a position in Bioverativ Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Roberts, Glore & Co's Bioverativ Inc. Common Stock position peaked at $392K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Roberts, Glore & Co's 13F filing for Q1 2018, filed 8 May 2018.